What is the 13F Pro Quality Score for ACAD?

13F Pro ranks ACADIA PHARMACEUTICALS INC (ACAD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACAD's current score at https://13fpro.ai/company/ACAD (free sign-up required for the full ranking).

Which hedge funds own the most ACAD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ACAD include BAKER BROS. ADVISORS, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ACAD as soon as new 13F filings post.

Where does 13F Pro source ACAD data?

All ACADIA PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ACADIA PHARMACEUTICALS INC files with the SEC under CIK 1070494. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACAD in?

ACADIA PHARMACEUTICALS INC (ACAD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ACAD's revenue?

Per ACADIA PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: NUPLAZID ($183.1M); DAYBUE products ($124.8M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ACAD.

What are ACAD's largest expenses?

ACADIA PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($160.3M); Research and development ($81.6M); Cost of product sales ($28.3M). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ACAD research updated on 13F Pro?

ACAD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ACADIA PHARMACEUTICALS INC(ACAD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1070494 ACAD stock profile & AI dashboard →

13F Pro Quality Score

67.8/100

Rank #346 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

67.2/100

Profitability

94.4/100

Balance Sheet

97.6/100

Earnings Quality

54.4/100

Free Cash Flow

61.3/100

Institutional Flow

34.6/100

Revenue Scale

52.3/100

Dilution Risk

25.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ACAD Scores 68/100

exact factor attribution · 2026-09-12

ACAD's composite is driven by profitability and capital efficiency, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+6.7 pts

94th pct

Capital efficiency

+4.8 pts

98th pct

Revenue growth

+3.4 pts

67th pct

Earnings growth

+2.5 pts

99th pct

Free cash flow

+1.7 pts

61th pct

Earnings quality

+0.4 pts

54th pct

Scale

+0.3 pts

52th pct

Institutional flow

-0.8 pts

35th pct

Shareholder dilution

-1.2 pts

25th pct

Latest change (2026-08-05): 70 → 63 · ↓ Revenue growth 83→56

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ACAD Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for ACADIA PHARMACEUTICALS INC (ACAD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACAD at 67.8/100 on a 32-signal composite quality model, placing it at rank #346 of 2,960 stocks — the top 25% of the AI-ranked universe. ACAD scores in the top quartile across balance sheet strength (97.6), profitability (94.4). Areas of concern include institutional flow (34.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ACADIA PHARMACEUTICALS INC reports quarterly revenue of $308.0M, net income of $31.5M, an operating margin of 12.3%. Top institutional holders of ACAD by reported 13-F value include BAKER BROS. ADVISORS, BlackRock, STATE STREET, based on the most recent SEC filings. ACAD trades on the Nasdaq exchange and files with the SEC under CIK 1070494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACAD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACADIA PHARMACEUTICALS INC directly from SEC EDGAR. ACADIA PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 23 and 72 since 2021, currently 67.8 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.

✦

Fun facts about ACADIA PHARMACEUTICALS INC

Quirks, history, and lore behind ACAD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-to-mid cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of a few hundred million dollars, driven almost entirely by a single approved drug — a high-risk, high-reward model familiar to specialty pharma investors.
3
The History
Founded in the early 2000s, the company spent years in clinical-stage limbo before winning a landmark FDA approval in 2016 for a drug targeting a notoriously hard-to-treat neurological condition.
4
The Secret
Its flagship drug works on the serotonin 5-HT2A receptor — a mechanism shared with certain psychedelics — making it a pioneer in central nervous system pharmacology.
5
The Lore
Its approved drug, pimavanserin, was the first new treatment for Parkinson's disease psychosis in decades — a condition most big pharma had quietly given up on.
6
The Giveaway
Ticker rhymes with a scenic national park in Maine, and its drug Nuplazid remains the only FDA-approved therapy specifically for Parkinson's disease psychosis.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ACAD's Business? Latest 10-Q Breakdown

✓ 17/17 datapoints verified

AI-extracted from ACADIA PHARMACEUTICALS INC's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net product sales rose to $308.0 million from $264.6 million a year ago, but SG&A jumped to $160.3 million, holding operating income to $37.8 million.

Biggest Revenue Drivers

NUPLAZID$183.1M

Increase of $14.7 million due to growth in NUPLAZID unit sales in 2026 compared to 2025

DAYBUE products$124.8M

Increase of $28.7 million due to growth in DAYBUE unit sales and a higher average net selling price

Biggest Revenue Drivers

Total revenue: $308.0M

NUPLAZID$183.1M

Increase of $14.7 million due to growth in NUPLAZID unit sales in 2026 compared to 2025

DAYBUE products$124.8M

Increase of $28.7 million due to growth in DAYBUE unit sales and a higher average net selling price

Largest Expense Items

Selling, general and administrative$160.3M

Increased expenditures for DAYBUE products and NUPLAZID in the U.S., including recent expansion of the DAYBUE and NUPLAZID teams

Research and development$81.6M

Increased expenditures for remlifanserin and ACP-211, offset by reduced spend on studies ending in 2025

Cost of product sales$28.3M

Approximately 9% of net product sales versus 8% a year ago; relatively flat as a percentage

Margins: Cost of product sales was approximately 9% of net product sales versus 8% a year earlier, which the filing describes as relatively flat.

Watch Items from the Filing

Two products generate all revenue; substantially all sales are to customers in North America, concentrating commercial and geographic risk.
Operating expenses grew to $270.1 million from $232.2 million, outpacing revenue growth and limiting operating income to $37.8 million.
Company may be required to make milestone payments up to $3.6 billion in aggregate for pipeline candidates.
Securities class action heading to trial: mandatory settlement conference August 17, 2026; no amounts accrued beyond attorneys' fees, exposure unestimable.
CHMP adopted a positive opinion in June 2026 recommending EU marketing authorization for trofinetide (DAYBU) in Rett syndrome.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$308.0M

Net Income

Q2 2026

$31.5M

Free Cash Flow

Q2 2026

$95.7M

Operating Margin

Q2 2026

12.3%

ROIC

Q2 2026

11.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.9% YoY

$1.07BFY 2025

FY22 $517.2MFY23 $726.4MFY24 $957.8MFY25 $1.07B

Net Income

+72.7% YoY

$391.0MFY 2025

FY22 $-216.0MFY23 $-61.3MFY24 $226.5MFY25 $391.0M

Operating Income

-54.6% YoY

$104.8MFY 2025

FY22 $-223.6MFY23 $-73.4MFY24 $230.8MFY25 $104.8M

EPS (Diluted)

+69.1% YoY

$2.30FY 2025

FY22 $-1.34FY23 $-0.37FY24 $1.36FY25 $2.30

Total Assets

+31.7% YoY

$1.56BFY 2025

FY22 $587.8MFY23 $749.0MFY24 $1.19BFY25 $1.56B

Op. Cash Flow

-30.4% YoY

$109.8MFY 2025

FY22 $-114.0MFY23 $16.7MFY24 $157.7MFY25 $109.8M

Free Cash Flow

-33.1% YoY

$105.1MFY 2025

FY22 $-114.0MFY23 $16.7MFY24 $157.2MFY25 $105.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.07B +11.9%	$957.8M +31.8%	$726.4M +40.4%	$517.2M +6.8%	$484.1M +9.6%	$441.8M
Net Income	$391.0M +72.7%	$226.5M +469.5%	$-61.3M +71.6%	$-216.0M -28.7%	$-167.9M +40.4%	$-281.6M
Operating Income	$104.8M -54.6%	$230.8M +414.5%	$-73.4M +67.2%	$-223.6M -31.2%	$-170.4M +40.5%	$-286.6M
EPS (Diluted)	$2.30 +69.1%	$1.36 +467.6%	$-0.37 +72.4%	$-1.34 -27.6%	$-1.05 +41.3%	$-1.79
Total Assets	$1.56B +31.7%	$1.19B +58.6%	$749.0M +27.4%	$587.8M -16.0%	$700.1M -10.5%	$782.6M
Operating Cash Flow	$109.8M -30.4%	$157.7M +844.3%	$16.7M +114.6%	$-114.0M +9.3%	$-125.7M +7.7%	$-136.2M
Free Cash Flow	$105.1M -33.1%	$157.2M +844.0%	$16.7M +114.6%	$-114.0M +10.1%	$-126.8M +11.8%	$-143.8M

Get alerted when ACAD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ACADIA PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACAD

BAKER BROS. ADVISORS LP
$1.1B42,912,904 sh
BlackRock, Inc.
$569.6M22,515,173 sh
STATE STREET CORP
$229.6M9,076,212 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$223.6M8,838,450 sh
RTW INVESTMENTS, LP
$180.8M7,144,524 sh
VANGUARD CAPITAL MANAGEMENT LLC
$145.8M5,763,750 sh
DIMENSIONAL FUND ADVISORS LP
$93.5M3,694,988 sh
GEODE CAPITAL MANAGEMENT, LLC
$85.0M3,358,129 sh
GOLDMAN SACHS GROUP INC
$65.3M2,580,115 sh
Qube Research & Technologies Ltd
$61.9M2,446,610 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$1.1B	42,912,904
BlackRock, Inc.	$569.6M	22,515,173
STATE STREET CORP	$229.6M	9,076,212
VANGUARD PORTFOLIO MANAGEMENT LLC	$223.6M	8,838,450
RTW INVESTMENTS, LP	$180.8M	7,144,524
VANGUARD CAPITAL MANAGEMENT LLC	$145.8M	5,763,750
DIMENSIONAL FUND ADVISORS LP	$93.5M	3,694,988
GEODE CAPITAL MANAGEMENT, LLC	$85.0M	3,358,129
GOLDMAN SACHS GROUP INC	$65.3M	2,580,115
Qube Research & Technologies Ltd	$61.9M	2,446,610

Companies Similar to ACAD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 15 shared holders

BAKER BROS. ADVISORS LP RICE HALL JAMES & ASSOCIATES, LLC BRAIDWELL LP

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

Hennion & Walsh Asset Management, Inc.CenterBook Partners LP Virtus Investment Advisers, LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 19 shared holders

Artisan Partners Limited Partnership FRED ALGER MANAGEMENT, LLC JUPITER ASSET MANAGEMENT LTD

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 26 shared holders

Edgestream Partners, L.P.SPHERA FUNDS MANAGEMENT LTD.TFG Asset Management GP Ltd

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 17 shared holders

BRAIDWELL LP Frazier Life Sciences Management, L.P.TFG Asset Management GP Ltd

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 15 shared holders

Artisan Partners Limited Partnership BRAIDWELL LP Edgestream Partners, L.P.

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 10 shared holders

BRAIDWELL LP NORDEA INVESTMENT MANAGEMENT AB Emerald Investment Advisers, LLC

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 13 shared holders

RTW INVESTMENTS, LP BRAIDWELL LP RICE HALL JAMES & ASSOCIATES, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACAD on your watchlist

Track score changes the day ACADIA PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACAD a good stock to buy?

13F Pro's AI-powered analysis of ACADIA PHARMACEUTICALS INC (ACAD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACAD are available on the ACAD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACAD is classified as a mid company.

Which hedge funds own ACAD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACAD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACADIA PHARMACEUTICALS INC's investment landscape.